Law.com Subscribers SAVE 30%

Call 855-808-4530 or email [email protected] to receive your discount on a new subscription.

Search

We found 1,279 results for "Medical Malpractice Law & Strategy"...

The 'Culpable Conduct' Defense
August 02, 2013
Blameworthy conduct by the plaintiff in a med mal action can take the form of failing to follow medical advice, refusing or neglecting recommended treatment, or intentionally providing an incomplete or misleading medical history.
Verdicts
July 30, 2013
In-depth analysis of recent important cases.
Med Mal News
July 30, 2013
Analysis of key rulings.
Drug & Device News
July 30, 2013
A look at several rulings.
The Media
July 30, 2013
How often do we hear that "everybody sues" in the United States, and that there are "jackpot juries" handing out huge sums of money to undeserving plaintiffs? Is the media to blame for these skewed beliefs or is the media accurate in its portrayal of the tort system, especially the medical malpractice system?
Suits Against Generic Pharm Manufacturers
July 29, 2013
What a recent Supreme Court decision does is to effectively immunize pharmaceutical generics manufacturers from state tort liability when they use FDA-approved labels for their products deemed equivalent to brand-name FDA-approved drugs.
Verdicts
June 21, 2013
An in-depth look at recent important rulings.
Med Mal News
June 21, 2013
A look at several recent news items.
Drug & Device News
June 21, 2013
A look at several key cases.
Dangerous Patients and the Tarasoff Doctrine
June 21, 2013
Psychiatrists and other mental health practitioners must know the reporting laws in their own jurisdictions, and take the required steps under those laws, if they want to avoid liability when a patient follows through on a threat to harm someone else.

MOST POPULAR STORIES

  • Surveys in Patent Infringement Litigation: The Next Frontier
    Most experienced intellectual property attorneys understand the significant role surveys play in trademark infringement and other Lanham Act cases, but relatively few are likely to have considered the use of such research in patent infringement matters. That could soon change in light of the recent admission of a survey into evidence in <i>Applera Corporation, et al. v. MJ Research, Inc., et al.</i>, No. 3:98cv1201 (D. Conn. Aug. 26, 2005). The survey evidence, which showed that 96% of the defendant's customers used its products to perform a patented process, was admitted as evidence in support of a claim of inducement to infringe. The court admitted the survey into evidence over various objections by the defendant, who had argued that the inducement claim could not be proven without the survey.
    Read More ›
  • In the Spotlight
    On May 9, 2003, the U.S. Attorney's Office for the District of Massachusetts announced that Bayer Corporation, the pharmaceutical manufacturer, had been sentenced and ordered to pay a criminal fine of $5,590,800 stemming from its earlier plea of guilty to violating the Federal Prescription Drug Marketing Act by failing to list with the FDA its drug product, Cipro, that was privately labeled for an HMO. Such listing is required under the federal Food, Drug &amp; Cosmetic Act. The Federal Prescription Drug Marketing Act, Pub. L. 100-293, enacted on April 22, 1988, as modified on August 26, 1992 by the Prescription Drug Amendments (PDA) Pub. L. 102-353, 106 Stat. 941, amended sections 301, 303, 503, and 801 of the Federal Food, Drug, and Cosmetic Act, codified at 21 U.S.C. '' 331, 333, 353, 381, to establish requirements for distributing prescription drug samples.
    Read More ›